{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:58:57Z","timestamp":1794092337490,"version":"4.8.0"},"reference-count":52,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Continuous subcutaneous apomorphine infusion (CSAI) is a standard of care treatment in advanced Parkinson's disease (PD) to treat motor fluctuations. However, literature about its long-term data is scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to report about CSAI tolerance and discontinuation predictors in a large monocentric cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive PD patients who had CSAI were included. CSAI duration, discontinuation rates at 3, 12, 24, 36, 48, and 60 months, demographic data, MDS-UPDRS motor score, adverse events (AEs), discontinuation reasons and predictive factors were analyzed with logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 208 patients were included from 1999 to 2023 (51% male; age: 67.4\u2009\u00b1\u20098.3 years; PD duration: 11.2\u2009\u00b1\u20095.0 years). In the overall group, CSAI duration was 25.0\u2009\u00b1\u200932.9 months (median: 13.0, range: 0.1\u2013260.0). Ninety-five patients (45.7%) discontinued CSAI after 12.7\u2009\u00b1\u200915.3 months (median: 8.0). Main discontinuation causes were switching to deep brain stimulation (44.2%) and low efficacy (15.8%). Sixty% of discontinuations occurred within the first year. CSAI duration was the only significant difference between ongoing CSAI (116) and discontinued patients (35.4\u2009\u00b1\u200939.7 vs. 11.1\u2009\u00b1\u200918.4 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), after excluding 42 CSAI-to-DBS. About 79.8% patients had AEs, mainly hallucinations (41.3%) and nodules (24.0%). The best discontinuation predictors were CSAI duration and baseline\n                      <jats:italic>off<\/jats:italic>\n                      medication MDS-UPDRS motor score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results may help clinicians better select patients, anticipate and manage AEs, and predict CSAI discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x251344896","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T03:10:31Z","timestamp":1750043431000},"page":"970-981","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Twenty-five-year experience with apomorphine pump in Parkinson's disease: A real-life long-term retrospective tolerance study"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1272-5979","authenticated-orcid":false,"given":"Sina R","family":"Potel","sequence":"first","affiliation":[{"name":"Division of Neurology, Saint-Brieuc Hospital, Rennes University, Saint-Brieuc, France"},{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-3714","authenticated-orcid":false,"given":"Maria","family":"Chondrogiorgi","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"},{"name":"Medical School, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-791X","authenticated-orcid":false,"given":"Andrea","family":"Gozzi","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"},{"name":"Department of Neuroscience and Rehabilitation, Sant\u2019Anna University Hospital, Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0562-3834","authenticated-orcid":false,"given":"Sandrine","family":"Correia","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2385-7096","authenticated-orcid":false,"given":"Anna","family":"Castrioto","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2995-6762","authenticated-orcid":false,"given":"Sara","family":"Meoni","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5673-5149","authenticated-orcid":false,"given":"Pierre","family":"Pelissier","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-6131","authenticated-orcid":false,"given":"Emmanuelle","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-9993","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Fraix","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7968-5908","authenticated-orcid":false,"given":"Elena","family":"Moro","sequence":"additional","affiliation":[{"name":"Grenoble Institute Neurosciences, Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00218-X"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29066"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91193-2"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8106-3"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30239-4"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0619-3"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.12.003"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.12.024"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.11.020"},{"key":"e_1_3_4_11_2","first-page":"10","article-title":"Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson\u2019s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study","volume":"21","author":"Cochen de Cock V","year":"2022","unstructured":"Cochen de Cock V, Dodet P, Leu-Semenescu S, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson\u2019s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol 2022; 21: 10.","journal-title":"Lancet Neurol"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12416"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.06.008"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70077"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X241310727"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.09.022"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105859"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27626"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8477-0"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00194-7"},{"key":"e_1_3_4_21_2","first-page":"1361","article-title":"Use of apomorphine in the treatment of Parkinson\u2019s disease","volume":"20","author":"Pollak P","year":"1991","unstructured":"Pollak P, Gervason CL. Use of apomorphine in the treatment of Parkinson\u2019s disease. Presse Med 1991; 20: 1361\u20131364.","journal-title":"Presse Med"},{"key":"e_1_3_4_22_2","first-page":"591","article-title":"Apomorphine and Parkinson\u2019s disease. A major therapeutical progress","volume":"42","author":"Pollak P","year":"1992","unstructured":"Pollak P, Gervason CL, Deffond D, et al. Apomorphine and Parkinson\u2019s disease. A major therapeutical progress. Rev Prat 1992; 42: 591\u2013593.","journal-title":"Rev Prat"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-010-0556-7"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1502165"},{"key":"e_1_3_4_25_2","first-page":"153","volume-title":"Recent developments in parkinsons disease","author":"Fahn S","year":"1987","unstructured":"Fahn S, Elton R. UPDRS Program members. Unified parkinsons disease rating scale. In: Recent developments in parkinsons disease. Florham Park, NJ: Macmillan Healthcare Information, 1987, pp.153\u2013163."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1988.00520350032011"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23429"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29410"},{"key":"e_1_3_4_32_2","unstructured":"Ubezio BS. Parkinson\u2019s disease infusion pump. Can\u00e8. Can\u00e8 infusion system Infusion pumps portable microinfusers https:\/\/canespa.it\/en\/infusion-pump-parkinson.html (accessed 26 December 2024)."},{"key":"e_1_3_4_33_2","unstructured":"SO-CONNECT infusion pump documentation. So connect https:\/\/www.so-connect.eu\/so-connect-infusion-pump-documentation\/ (accessed 26 December 2024)."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25122"},{"key":"e_1_3_4_35_2","unstructured":"jamovi - open statistical software for the desktop and cloud https:\/\/www.jamovi.org\/ (accessed 26 December 2024)."},{"key":"e_1_3_4_36_2","unstructured":"The Comprehensive R Archive Network https:\/\/cran.r-project.org\/ (accessed 26 December 2024)."},{"key":"e_1_3_4_37_2","unstructured":"Analysis for Clinicopathological Research \u2022 ClinicoPath https:\/\/www.serdarbalci.com\/ClinicoPathJamoviModule\/ (accessed 26 December 2024)."},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197603112941101"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.27.9.875"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13810"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.09.025"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13378"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03920-5"},{"key":"e_1_3_4_44_2","first-page":"344","article-title":"Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease","volume":"50","author":"Benabid AL","year":"1987","unstructured":"Benabid AL, Pollak P, Louveau A, et al. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987; 50: 344\u2013346.","journal-title":"Appl Neurophysiol"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000098600"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.5603\/pjnns.102858"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-225105"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.09.018"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13926"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040254"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00533-1"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000361"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251344896","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X251344896","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251344896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:51:40Z","timestamp":1777589500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X251344896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/1877718X251344896"],"URL":"https:\/\/doi.org\/10.1177\/1877718x251344896","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}